A B S T R A C T Uterine production of PGI2 (prostacyclin) was quantitated in late pregnant dogs to evaluate if PGI2 could act as a circulating vasodepressor substance in pregnancy. In five anesthetized, laparotomized dogs, the uterine venous plasma concentration of 6-keto PGF,a (the in vitro hydrolysis product of PGI2) was 6.7±1.9 nglml and the arterial plasma concentration was 2.6±0.8 ng/ml. In four nonpregnant female dogs the arterial plasma concentration of 6-keto PGFi,a was consistently below 0.2 ng/ml. In eight pregnant dogs we also evaluated the ability of the pregnant uterus to inactivate PGI2 by comparing the hypotensive response to increasing doses of PGI2 infused into the uterine artery to the hypotensive response to increasing doses of PGI2 infused into the inferior vena cava. In addition, the effect of PGI2 infused into the uterine artery on uterine blood flow and intraamniotic fluid pressure was evaluated. The dose-response curves of intrauterine and intravenous PGI2 in causing systemic hypotension were identical suggesting that the pregnant uterus does not inactivate infused PGI2. Intrauterine PGI2 had no consistent effect on uterine hemodynamics although it did increase intraamniotic fluid pressure significantly. These data demonstrate that the pregnant uterus has the capacity to produce large quantities of PGI2 which is not inactivated in the uterus and therefore can appear in the arterial blood to exert a systemic vasodepressor effect.
INTRODUCTION
Despite salt and water retention and a large increase in cardiac output, pregnancy is associated with a slight decrease in mean arterial pressure (1) . This decrease in arterial pressure is secondary to an even larger decrease Dr. Gerber is an Established Investigator of the American Heart Association.
Received for publication 21 July 1980 and in revised form 10 October 1980. 632 in total peripheral vascular resistance. The mediator of the decreased peripheral vascular resistance is not known, but prostaglandins have been implicated to play a role in this effect. We have recently reported that the late pregnant uterus in the dog is capable of synthesizing large amounts ofprostaglandin E2 (PGE2)' which is a potent vasodepressor agent (2) . Even though the uterine venous levels of PGE2 were in the nanogram per milliliter range, the arterial PGE2 levels were too low to detect. Because of the large capacity of the lungs to metabolize PGE2, it is unlikely that PGE2 could have a systemic role in controlling blood pressure from a distant organ like the pregnant uterus. However, prostacyclin (PGI2), unlike PGE2, travels through the lung intact making it a good candidate for a circulating depressor hormone (3) .
The present study was undertaken to evaluate the capacity of PGI2 production by the pregnant uterus in the dog and to study the ability of the pregnant uterus to inactivate PGI2.
METHODS (A)
. Eight mongrel dogs, weighing between 16-28 kg, in late pregnancy but before labor, were anesthetized using pentobarbital, 30 mg/kg, and placed on a positive pressure respirator pump. One femoral artery and one femoral vein were catheterized for blood pressure monitoring, and drug and fluid administration, respectively. Through a low abdominal incision, the pregnant uterus was exposed and one of the uterine veins was cannulated from a smaller venous branch. The right main uterine artery was identified and a noneannulating electromagnetic flow probe was placed around the artery to measure continuously uterine blood flow via a flowmeter (Statham Instruments, Inc., Oxnard, Calif.). The uterine artery was then punctured with a curved 27-gauge needle connected to a polyethylene tube for the intrauterine infusion of PGI2. Amniotic fluid pressure was continuously monitored on the right 'Abbreviations used in this paper: 6-keto PGF,,,, 6-keto prostaglandin F,lo; PGE2, prostaglandin E2; PGI2, prostacyclin.
side through a floating catheter in the amniotic sac attached to a pressure transducer. After the surgery, we allowed -45 min for stabilization.
In five of the animals 30 ml of uterine venous and 30 ml of arterial blood were withdrawn into plastic syringes containing 0.1 vol of 3.8% sodium citrate and 1 mM indomethacin for the analysis of the plasma for 6-keto PGF,lo the acid hydrolysis product of PGI2.
To evaluate the hemodynamic and uterine contractile effects of PGI2, plus the ability of the pregnant uterus to inactivate PGI2, we infused PGI2 first into the uterine artery and then into the inferior vena cava at doses of 3, 10, 30, and 100 ng/kg per min. Mean arterial pressure, uterine blood flow, and intraamniotic fluid pressure were continuously monitored. Between doses of PGI2, a 30-min stabilization period was introduced to allow all the hemodynamic parameters to return to base line.
(B). Four nonpregnant female dogs weighing between 18-25 kg were anesthetized with 30 mg/kg pentobarbital i.v. and placed on a positive pressure respirator pump. The femoral artery and vein were catheterized as with the pregnant dogs. Through a midabdominal incision the nonpregnant uterus was identified and manipulated to a similar degree as with the eight pregnant animals in section A. The incision was then closed and the animals were allowed to stabilize for 45 min. When the animals were hemodynamically stable, 30 ml of arterial blood was collected in plastic syringes containing 0.1 vol of3.8% sodium citrate and 1 mM indomethacin for the subsequent analysis of the plasma for the measurement of 6-keto PGFia.
(C). Analysis of6-keto PGF1, concentration in the plasma. 500 ng of tetradeutero 6-keto PGF,, (a gift of Dr. John Pike, Upjohn Co., Kalamazoo, Mich.) was added to the plasma as the internal standard and 100,000 cpm of tritiated 6-keto PGFI, (New England Nuclear, Boston, Mass.) was added to the plasma to facilitate the isolation and purification of the prostaglandin. The prostaglandin was extracted into 3 vol of ethyl acetate after acidification of the plasma to pH 3 with 1 N HCl. The extract was initially purified over an open silicic acid column and eluted with chloroform (96)/methanol (4)/ acetic acid (0.1) (vol/vol/vol). The extract was further purified and separated by using two high pressure liquid chromatography steps using the fatty acid column anid ,uPorasil columns (Waters Associates, Inc., Milford, Mass.) sequentially. The purified 6-keto PGFIa was then derivatized to the methoxime, methyl ester, trimethylsilyl derivative.
The derivatized prostaglandin was analyzed by gas chromatography-mass spectrometer under electron impact conditions (70 eV). The gas chromatography was performed with a silanized glass column containing 3% OV 101 on Gas-Chrom 120/ 140 (Applied Science Labs., Inc., State College, Pa.) at an oven temperature of 240-250°C. The prostaglandin was analyzed on a Finnigan 3200 quadrupole mass spectrometer using selected ion monitoring under control of a Finnigan 6100 data system (Finnigan Corp., Sunnyvale, Calif.). The ion pairs (mass/energy) 598 and 602 were monitored for estimating the ratio of D0/D4 6-keto prostaglandin F1, (6-keto PGFia) in the biologic samples. The principles and details of these procedures have been recently described by Green et al. (4).
The detection limit for estimating 6-keto PGFIa plasma concentrations using 15 ml of plasma was 200 pg/ml. This method measures both PGI2, which hydrolyzes to 6-keto PGFia during the work-up of the plasma, as well as preformed 6-keto PGF1,,, which is in plasma at the time of sampling. In vivo, PGI2 is thought to be metabolized predominately to 15-keto PGI2 and then to 6,15 diketo PGFia and 6-keto PGF1G is probably not a major in vivo product of PGI2 (5, 6) . 
RESULTS
In the five pregnant dogs, the mean uterine vein and arterial plasma concentrations of 6-keto PGFiet were 6.68±1.92 and 2.62±0.85 ng/ml, respectively. In the nonpregnant female dogs, the arterial plasma concentrations of 6-keto PGFi,, were below the detection limit of our assay in all four of the animals (<200 pg/ml) ( Table I) .
Infusion of increasing concentrations of PGI2 resulted in a progressive decrease in mean arterial pressure. There was no difference in the hypotensive response to PGI2 whether the prostaglandin was infused intravenously or into the pregnant uterus (Fig. 1) . This suggests that very little if any of the PGI2 traveling through the uterus is metabolized to inactive compounds. Since PGI2 is not inactivated by the lungs, PGI2 produced by the pregnant uterus would be expected to travel to the systemic circulation intact. Our data showing high uterine venous as well as arterial plasma 6-keto PGFi,, concentrations are consistent with the lack of the lung metabolism of PGI2. Although the metabolism of intrauterine-generated PGI2 may be different than the metabolism ofinfused PGI2, this suggesting a contractile effect of the prostaglandin on the pregnant myometriumn (Table II) were not significant. This is in contrast to the effects of PGI2 on other vascular beds where the increases in organ blood flows were maintained for the duration of the PGI2 infusion (7, 8) . The hypotensive effect of the higher doses of PGI2 was maintained for the duration of the PGI2 infusion suggesting that the vascular resistance in organs other than the uterus remained below control levels. The two highest doses of intrauterine PGI2 infusion significantly increased intraamniotic fluid pressure, Although we were measuring 6-keto PGF1<, concentration in the plasma which is a composite of both intact PGI2 (hydrolyzed to 6-keto PGF,ia ex vivo) and already present 6-keto PGFia, the uterus does not synthesize 6-keto PGFia, but produces PGI2, which is then nonenzymatically hydrolyzed to 6-keto PGFi,,a. Thus, the uterine venous minus arterial concentration of 6- keto PGFlG, most likely represents net PGI2 synthesis.
Since the half-life of PGI2 dissolved in blood is 3 min (13) , and the lung does not metabolize PGI2, a significant portion of the uterine synthesized PGI2 could reach the arterial circulation unchanged. The reports that angiotensin II stimulation of PGI2 synthesis in the canine lung (14) and kidney (15) results in a platelet effect also strongly argues in favor of PGI2 being released intact from organs.
The hypothesis that PGI2 may be an important circulating vasodepressor hormone in pregnancy is attractive from several viewpoints. Pregnancy is associated with a decline in blood pressure and peripheral vascular resistance, the mechanism of which is unclear. Indeed the mean blood pressure in our anesthetized, pregnant dogs was significantly lower than in the four anesthetized, nonpregnant controls (112±4 vs. 141±9 mm Hg; P < 0.05, unpaired t test). The possibility that circulating PGI2 is partially responsible for the decrease in peripheral vascular resistance in pregnancy gains substance from our data. In addition, pregnancy is associated with elevated plasma renin activity and vascular angiotensin resistance (16) . This vascular insensitivity to angiotensin is analogous to that seen in Bartter's syndrome, where prostaglandin inhibition can ameliorate the vascular defects of the syndrome (17) . Thus, it is conceivable that the high concentration of circulating PGI2 is responsible for both the elevated plasma renin activity as well as angiotensin insensitivity in pregnancy.
The actual amount of PGI2 secreted by the pregnant uterus in the unanesthetized, uninstrumented dog could be several fold less than in the anesthetized and laparotomized animal. Both the stress ofanesthesia and laparotomy has been shown to increase prostaglandin production by the kidney (18) . Nonetheless, in the four nonpregnant dogs that also underwent anesthesia and laparotomy the arterial plasma concentrations of 6-keto PGF,i,, were below the sensitivity of our assay suggesting that indeed the capacity of the pregnant uterus to make PGI2 must be very high and that anesthesia, per se, cannot explain our results.
We can conclude from our data that PGI2, measured as 6-keto PGF,ia, is produced by the pregnant uterus in the dog and that the arterial concentration of 6-keto PGF,<, in pregnant animals is elevated above that ofthe nonpregnant dogs. In addition, although the pregnant uterus makes PGI2, probably does not play any role in inactivating it. Thus, uterine PGI2 is a likely mediator to contribute to the lowered systemic vascular resistance in pregnancy.
